GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/IBD/AI Reads Pediatric IBD Biopsies: Cellular and Molecular Gastro and Hepato | June 2026

AI Reads Pediatric IBD Biopsies: Cellular and Molecular Gastro and Hepato | June 2026

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated June 1, 2026

Quick Answer

• Histopathology remains a cornerstone for diagnosing pediatric inflammatory bowel disease, but differentiating Crohn’s disease from ulcerative colitis can be challenging, especially in young children. • This study evaluated whether artificial intelligence could automatically identify key histological features from routine endoscopic biopsy whole-slide images.


  • Histopathology remains a cornerstone for diagnosing pediatric inflammatory bowel disease, but differentiating Crohn’s disease from ulcerative colitis can be challenging, especially in young children.
  • This study evaluated whether artificial intelligence could automatically identify key histological features from routine endoscopic biopsy whole-slide images.
  • Researchers developed three computer vision models using convolutional neural networks and multiple-instance learning, a technique particularly useful when precise lesion-level annotation is unavailable.
  • The first model differentiated normal versus abnormal tissue with excellent performance, achieving an AUC of 0.91.
  • The second model identified active inflammation, achieving an AUC of 0.92.
  • The third model detected chronic architectural distortion, achieving an AUC of 0.93.
  • Overall model performance was strong despite using a weakly supervised learning approach, suggesting that meaningful pathological signals are present within routine whole-slide images.
  • The study demonstrates that AI can recognize inflammatory and structural patterns typically assessed by gastrointestinal pathologists.
  • Importantly, the models were developed from real-world pediatric endoscopic biopsy specimens rather than highly curated research datasets.
  • The findings support the concept that AI could function as a pathology decision-support tool rather than replacing pathologists.
  • Potential future applications include:

Automated screening of biopsy slides

Standardization of histological interpretation

Reduction of interobserver variability

Faster reporting workflows

Objective disease activity assessment

  • For pediatric IBD, where early diagnosis can significantly influence treatment selection and long-term outcomes, such tools may become increasingly valuable.
  • The study does not yet provide direct Crohn’s disease versus ulcerative colitis classification, but establishes the foundation for future disease-specific diagnostic algorithms.
  • Larger multicenter validation studies and integration with clinical, endoscopic, and molecular data will be required before routine clinical implementation.

Bottom line: This study demonstrates that artificial intelligence can accurately identify abnormal tissue, active inflammation, and chronic architectural changes in pediatric IBD biopsy slides, highlighting the growing role of computer vision as a diagnostic support tool in gastrointestinal pathology.

Related Q&A

IBD Across Ethnicities: Gastroenterology | July 2026

Introduction: The global incidence of inflammatory bowel disease (IBD) continues to rise, particularly in newly industrialized countries. This comprehensive systematic review evaluated how race, ethnicity, geography, and migration influence the clinical phenotype and outcomes of...

Moving Beyond the "Wait to Fail" Strategy in ASUC: FG | 2026

Introduction: Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues...

FMT in Ulcerative Colitis: JGH | July 2026

Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising global burden. Although current therapies are effective, many patients fail treatment or experience adverse effects. Fecal microbiota transplantation (FMT) has emerged as...

Engineering Immune Cell Therapies for IBD: Nat Re Gastroe & Hepato | June 2026

Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than...

Real-World IBD Patients Rarely Meet Clinical Trial Criteria: AJG | June 2026

Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine clinical practice, raising concerns about the real-world...

Mirikizumab in Ulcerative Colitis: JCC | June 2026

Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer